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S370 Poster Session II(35.9%) and 8 (20.51%) pts had a HLAmismatched donor. Therapy
associated complications identified included hyperacute GVHD
(13pts [33.3%]), acute renal failure (13 pts [33.3%]), hemolysis (14
pts [35.9%]), neuro-toxicity (7 pts [17.95%]), cytopenias (10 pts
[25.6%]), dyslipidemia (6 pts [15.4%]) and skin changes (2 pts
[5.13%]). 15 pts (38.5%) had GrIII-IV GVHD. 12 pts (30.8%)
died of who 3 (25%) were directly related to the siro-tac associated
toxicity.
Conclusions:We conclude that the sirolimus-tacrolimus combina-
tion GVHD prophylaxis regimen, is associated with considerable
toxicities that contribute to the transplant associated morbidity
and mortality in the allogeneic hematopoietic stem cell transplanta-
tion setting, not attributable to the conditioning regimen. Therefore
this regimen should be used cautiously outside of a clinical trial.
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RESTING REGULATORY T LYMPHOCYTES: A BIOMARKER FOR CHRONIC
GVHD
Parkman, R., Masinsin, B., Mahadeo, K.M., Kapoor, N., Abdel-
Azim, H.M., Shah, A.J. Children’s Hospital Los Angeles, Los Angeles, CA
T cell depletion and peri-transplant serotherapy have reduced the
incidence and severity of acute graft versus host disease (GVHD);
however, chronic GVHD continues to be a major clinical limitation
to the increased use of hematopoietic stem cell transplantation
(HSCT). Deficiencies in naturally occurring regulatory T lympho-
cytes (Treg) have been hypothesized to contribute to chronic
GVHD. The evaluation of the role of Treg lymphocytes in the path-
ogenesis of chronic GVHD have been limited by a lack of well-de-
fined immunophenotypic characterization of Treg lymphocytes.
Most previous evaluations of Treg lymphocytes inHSCT recipients,
which used either CD25 and/or FoxP3 expression, were confounded
by the fact that activated conventional T lymphocytes (Tcon) ex-
pressed CD25 and FoxP3. We have performed a cross-sectional
analysis of pediatric HSCT recipients using theMiyara classification
of Treg lymphocytes. (Immunity 30:899, 2009) The Miyara classifi-
cation can distinguishes between Treg lymphocytes, both resting
and activated, and activated Tcon lymphocytes, permitting a more
accurate assessment of Treg in the HSCT setting. Pediatric
HSCT recipients more than 1 year post-HSCT were evaluated for
their resting (r) and activated (a) Treg lymphocytes and their r/a ratio
determined. (Table 1)
Table 1. Resting and Activated Treg Lymphocytes in HSCT
Recipients
rTreg aTregPatient r/a ratio
(% of total CD4
T lymphocytes x 1021)Allogeneic-
No hx of acute/chronic GVHD 17.3 6.2 4.7
Active chronic GVHD 6.4 1.8 3.5
Hx of chronic GVHD 14.0 6.8 3.2
Autologous 11.3 5.2 2.2
Normal Individuals 19.3 3.6 3.9Allogeneic HSCT recipients with no history of either acute or
chronic GVHD did not differ from normal individuals. Neither
did allogeneic recipients with only a history of acute GVHD nor
the recipients of autologousHSCT. Allogeneic recipients with active
chronic GVHD had reductions in both the percentage of resting
Treg lymphocytes (p 5 .02 compared to normal or recipients with
neither acute nor chronic GVHD) and of activated Treg lympho-
cytes (p 5 .002 compared to recipients without acute or chronic
GVHD and p5 .0008 compared to normals). Allogeneic recipients,
who have had the clinical resolution of their chronic GVHD, did not
differ from normal individuals. The clinical resolution of chronic
GVHD is associated with a normalization of both resting and acti-
vated Treg lymphocytes. The longitudinal evaluation of resting
Treg levels may aid in the management of chronic GVHD patients
and may predict when clinical improvement occurs.452
BORTEZOMIB FOR STEROID REFRACTORY ACUTE GRAFT VERSUS HOST
DISEASE (GVHD)
Wagner, J.L., Mookerjee, B., Filicko-O’Hara, J.E., Grosso, D.A.,
Flomenberg, N. Thomas Jefferson University Kimmel Cancer Center,
Philadelphia, PA
Steroid refractory GVHD remains a significant problem after
allogeneic HSCT with a mortality rate exceeding 90% in some
series and no standard for salvage treatment. Murine data suggest
bortezomib inhibits acute GVHD, but preserves graft-versus-tu-
mor effect. We sought to test whether the same activity could
be demonstrated in a clinical setting. Patients were eligible for
the trial if they had clinical or histological evidence of acute
GVHD and had been treated with 2mg/kg/day of methylprednis-
olone and had 1) either a minimum of 3 days of corticosteroids
with progressive disease or 2) a minimum of 7 days without a re-
sponse or 3) had progression when steroids were tapered to less
than 2mg/kg/day of methylprednisolone. Bortezomib was given
at a dose of 1.3mg/m2 administered as a bolus intravenous injec-
tion twice weekly for 2 weeks (days 1, 4, 8, 11) followed by a 10
day rest period constituting one 21 day treatment cycle. A com-
plete response (CR) was defined as no clinical or laboratory signs
of acute GVHD in all organs, and a partial response (PR) re-
quired at least a 1 grade reduction in overall GVHD scoring
in at least 1 organ system without worsening in others. Response
was determined on day 21 after the first cycle and every 3 weeks
until 3 months after the last cycle or death whichever came first.
After the 1st cycle, patients achieving CR or PR were treated
with additional cycles until they had a dose limiting toxicity or
a complete response, and patients without response were taken
off study and considered treatment failure. Three of 11 patients
treated were not evaluable for efficacy; 1 withdrew from the
study after less than 1 cycle without signs of toxicity, 1 died 1
week after receiving the 1st cycle of septic shock, and the 3rd pa-
tient developed a concomitant viral infection that could not be
distinguished from possible concomitant GVHD. Of the 8 evalu-
able patients 4 had no response and 4 had at least a partial re-
sponse. In the 4 patients with responses 2 were complete
responses and 2 were partial. Ten of the 11 patients have died,
2 of progressive disease, 6 of infection, 1 of hemorrhage and 1
of pulmonary toxicity. Whether bortezomib contributed to any
of these deaths was unclear. One of the partial responders was
taken off the study for peripheral neuropathy and is still alive
4.5 years later. In this small study bortezomib demonstrated
some activity in steroid refractory acute GVHD with some neu-
rotoxicity.453
LATENT CMV AND THE CD4+ T CELL TRANSCRIPTION PROGRAM IN PA-
TIENTS WITH CHRONIC GVHD
Astigarraga, C.C.1, Tabellini, L.1, Pergam, S.1, Bumgarner, T.1,
Fan, W.1, Grogan, B.1, Storer, B.1, Boeckh, M.1,2, Zaho, L.P.1,
Hansen, J.A.1,2 1Fred Hutchinson Cancer Research Center, Seattle,
WA; 2University of Washington, Seattle, WA
Latent CMV infection is known to have a life long effect on
the distribution of T cell subsets, but little is known about the
impact on cell function. We performed a gene expression analysis
in purified CD4+ T cells from 68 hematopoietic cell transplant
(HCT) recipients (median age 48; range 20-65) studied on aver-
age 5 years after HCT (median 4.75; range 1-20 years). The
study population included 38 patients with active chronic
GVHD (cGVHD) and 30 tolerant (TOL) patients. Tolerance
was defined by absence of signs, symptoms of cGVHD and im-
munosuppressive therapy (IST) for 3 months. Gene expression
was measured on Illumina bead arrays. CMV status was defined
by pre-transplant recipient CMV serology (by ELISA). There
was no recorded evidence of CMV reactivation at the time of
study. Nine of 93 candidate genes associated with immune func-
tion and inflammation were found to be associated CMV seros-
tatus in cGVHD patients at a significance threshold of p\0.05,
but only four genes (ITK; CD86; PLCG1; PIK3CB) were
Poster Session II S371associated with CMV serostatus in TOL patients. A multivariate
analysis including: acute GVHD, conditioning regimen, marrow
vs. PBSC; related vs. unrelated donor, matched vs. mismatched
donor, recipient age and time post-HCT was performed Table 1.
cGVHD patients had a profile consistent with T effector cell ac-
tivation that was not present in TOL.
The characteristic inflammatory environment, increased cytokine
production, immunosuppressive therapy and impaired T cell im-
mune reconstitution observed in cGVHD, may increase the risk of
CMV reactivation and subsequent upregulation of genes related to
T cell activation and effector functions. In contrast, tolerant patients
may have achieved greater immune reconstitution andmore effective
CMV surveillance and control.
T cell activation during cGVHD is a complex process that appears
to be influenced by latent CMV.
Table 1. Multivariate analysis
Active cGVHD TolerantCMV+ (n 5 17) vs
CMV-(n 5 21)CMV+ (n 5 11) vs
CMV-(n 5 19)ITK 0.023[
CD86 0.034[
PLCG1 0.033[
PIK3CB 0.005[
GZMB 0.024[
INFg 0.015[
IL4R 0.025YPTPN7 0.000[
PRF1 0.000[
GZMA 0.003[
PDCD1 0.008[
IL12RB1a 0.016[
IL12RB1b 0.000[Ydownregulated gene
[upregulated gene454
INDUCTION OF A GVHD-LIKE SYNDROME FOLLOWING ALLOGENEIC
BMT AND CsA THERAPY
Bryson, J.S.1,3,4, Brandon, J.A.3,4, Jennings, C.D.2,4, Kaplan, A.M.3,4
1University of Kentucky, Lexington, KY; 2University of Kentucky, Lex-
ington, KY; 3University of Kentucky, Lexington, KY; 4University of Ken-
tucky, Lexington, KY
Cyclosporine A (CsA) is a calcineurin inhibitor that is used to pre-
vent graft-versus-host disease (GVHD) following allogeneic hema-
topoietic stem cell (HSCT)/bone marrow transplantation (BMT).
While CsA is utilized for the prophylaxis of GVHD, many patients
develop GVHD while on, or after removal from therapy. A disorder
develops with clinical symptoms and pathology that is similar to al-
logeneicGVHDafter syngeneic BMTandCsA therapy and has been
termed, syngeneic GVHD (SGVHD). In mice, SGVHD is mediated
by CD4+ T cells and required an intact host microbiota for the dis-
ease to develop. Interestingly, it was recently shown that antibiotic-
responsive intestinal inflammation developed after cord blood stem
transplantation and treatment with calcineurin inhibitors as prophy-
laxis for the development of GVHD. Data will be presented that
demonstrates the induction of a GVHD-like disease following allo-
geneic BMT and CsA therapy in mice. We have termed this disease
CsA-induced pseudoGVHD (PGVHD). In this inducible disease,
pathology characteristic of GVHD occurs in the colon and liver.
Similar to the SGVHDmodel, increasedCD4+T cell responsiveness
against microbial antigens is associated with an increase in TH1/
TH17 immunity relative to control BMTanimals. Themechanism(s)
responsible for the induction of PGVHDare unknown.Whether the
development of this disorder is due to incomplete immunosuppres-
sion, altered immune regulation, generation of immunity against mi-
crobial antigens or a combination of these possibilities is currently
under investigation. The PGVHD model will shed light on thisquestion with an eye towards future development of novel therapies
to address this issue clinically.455
SYSTEMIC EFFECTS OF ORAL BUDESONIDE IN HEMATOPOIETIC TRANS-
PLANT: IMPLICATIONS OF DRUG INTERACTION WITH AZOLES
Obi, G.A.1, Fakih, R.E.L.2, Scholoff, A.1, Carrum, G.1, Kamble, R.T.1
1Baylor College of Medicine and the Methodist Hospital, Houston, TX;
2Baylor College of Medicine, Houston, TX
Oral budenoside (BUD) is commonly used as a topical adjunct in
graft-versus-host-disease (GVHD) of the gastrointestinal tract.
BUD possesses a high ratio of topical-to-systemic activity that limits
steroid toxicity. It is, however, inactivated via cytochrome P450 iso-
enzymes so that concomitant administration of azoles which com-
pete for this enzyme increases its bioavailability. The clinical
significance of such increased bioavailability after hematopoietic
stem cell transplantation is unknown.
The development of iatrogenic Cushing’s syndrome in a patient
receiving allogeneic hemopoietic stem cell transplantation (al-
loHSCT) who was taking BUD as the sole source of steroids, led
us to explore the frequency of Cushing’s disease or other manifesta-
tions of significant systemic exposure to exogenous steroids in pa-
tients who had received alloHSCT and were receiving both BUD
and an azole drug.We reviewed the medical charts of the 60 patients
who received an alloHSCT between January 2008 and August 2011.
Five patients (Table-1) met the criteria of diagnosis of acute or
chronic GVHD; continuation of BUD for a further 21 days or
more after cessation of systemic steroids; and concomitant adminis-
tration of an azole drug. The charts were reviewed for evidence of
clinical development of iatrogenic Cushing’s syndrome and for evi-
dence of abnormalities in morning plasma cortisol levels and serum
glucose levels.
BUD was initiated at 9 mg per day and the dose was titrated ac-
cording to response. All these patients were receiving either flucona-
zole (n 5 3) or voriconazole (n 5 2) for fungal prophylaxis.All had
suppression of morning plasma cortisol consistent with systemic ab-
sorbtion and significant plasma levels of the topically applied drug.
The patients also had rapid (within 3 weeks) onset of iatrogenic
Cushing’s syndrome, with median weight gain of 5.7 kg (range 5
4-7.1 kg). All patients developed facial mooning, central obesity
and glucose intolerance. Plasma cortisol remained at 1 ug/dl even
when BUD was titrated to 3mg/day, at which time exacerbation of
GUT and/or skin GvHD was seen, necessitating dose escalation.
Absolute neutrophil and lymphocyte counts remained unchanged
with no increased infections.
Hence the effect of combining azole-drugs with BUD is to consis-
tently increase systemic levels of the steroid sufficiently to induce
Cushing’s syndrome, reducing the selective benefit of this ‘‘topical’’
agent for gut GvHD in patients receiving both agents.
Table 1. Patients characteristics on BUD alone
GVHD/ BUD alone Cushing’sPatient/transplant Treatment duration (days) manifestation52, M, AML,
MIUD in CR-2,
BU/CY/AL,
tacrolimus
Grade II aGvHD,
skin, gut, liver,
Limited cGvHD,
skin, gut,
Prednisone,
BUD571* Plasma
cortisol 5 1 ug/dl,
weight gain 5 5.7 kg,
facial mooning,
central obesity,
glucose intolerance51, M, AML,
MRD in active
disease, BU/CY,
MTX,
tacrolimus
Grade II aGvHD,
skin,gut,
prednisone,
BUD62 Plasma cortisol 5 1ug/dl,
weight gain 5 4 kg facial
mooning, central obesity,
glucose intolerance67, M, AML,
MUD in CR-2,
FL/MEL/AL,
tacrolimus
Grade II aGvHD,
skin, gut,
Limited cGvHD,
skin, gut,
prednisone,
BUD151* Plasma Cortisol 5 1ug/dl,
weight gain 5 4.7 kg,
facial mooning, glucose
intolerance(Continued )
